The South Carolina site will be an advanced facility with medical device injection molding and fully automated assembly capabilities
July 18, 2022
NORTH CHARLESTON, S.C.—SHL Medical reported it is planning a new manufacturing site in the United States in response to growing market demand for its autoinjector product portfolio. The decision stems from SHL’s “strategic assessments in extending its production to North America,” the company said in a release.
The new U.S. site, covering approximately 270,000 square feet, will be located in North Charleston, South Carolina. Initial investments are reported to total $90 million. Operations are expected to launch by 2024, and SHL Medical is expected to create an estimated 165 local employment opportunities, the company said.
The South Carolina site will be an advanced facility with medical device injection molding and fully automated assembly capabilities. These expanded manufacturing capabilities in the U.S., together with SHL’s current final assembly, labeling, and packaging operations in Deerfield Beach, Florida, are expected to further fortify SHL’s offerings in delivering comprehensive services to its partners.
SHL Medical said it developed a long-term strategy in 2019 to address growing demand for its autoinjector products and to meet future manufacturing needs. In addition to its planned U.S. operation, SHL’s ongoing expansion includes plans for a new manufacturing site in Switzerland. The new production site in the U.S. will offer fully automated production facilities and a flexible supply chain with reduced distance to main markets, according to the release.
“Demand for SHL’s products has increased significantly. Therefore, we are speeding up our plans for a new plant in the U.S.,” said SHL Medical Chairman and CEO Ulrich Faessler, in the release. “Similar to our upcoming European site in Zug, Switzerland, the U.S. site will be a state-of-the-art, fully automated site. This expansion signifies SHL’s pledge to our advanced manufacturing strategy that will support our sustainability goals; and, at the same time, risk-mitigate supply chain disturbances through closer production with our customers, in light of various global events from the past two years.
“This further supports our customers with one-stop-shop capabilities, providing high-quality drug delivery systems to the end-users—the patients,” Faessler added.